Skip to main content
SpringerLink
Log in
Book cover

Konzepte zur Sicherheit in der Anästhesie pp 241–262Cite as

Risiko kolloidaler Lösungen und Grenzen der Hämodilution

  • Conference paper

  • 20 Accesses

Part of the book series: Klinische Anästhesiologie und Intensivtherapie ((KAI,volume 42))

Zusammenfassung

Die heute in der Klinik verwendeten kolloidalen Lösungen lassen sich einteilen in natürliche — Albumin, Plasmaproteinlösungen — und künstliche Kolloide — Dextran, Hydroxyäthylstärke (HES), Gelatine. Seit Jahrzehnten werden diese Lösungen zur Therapie des Volumenmangels, zur Therapie von Mikrozirkulationsstörungen und zur Prophylaxe von Thromboembolien in der Klinik eingesetzt. Die Lösungen von normalem Blutplasma und von Fresh-frozen-Plasma sollen hier nicht näher behandelt werden, da die Risiken ihrer Verwendung weitgehend denen der Transfusion homologer Blutkonserven entsprechen (Infektion, Immunmodulation).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aberg M (1979) The antithrombotic effect of dextran. Scand J Hematol (Suppl) 34: 61–69

    CAS  Google Scholar 

  2. Aberg M, Hedner U, Bergentz SE (1979) Effect of dextran on factor VIII (antihemophilic factor) and platelet function. Ann Surg 189: 243–273

    CAS  PubMed Central  PubMed  Google Scholar 

  3. Ahnefeld FW, Fischer F, Frey R, Kilian J, Schöning B (1979) Der Infusionszwischenfall nach künstlichen Plasmasubstituten im Meldekollektiv der Arzneimittelkommission. Medizinische Problematik, Prophylaxe und Soforttherapie. Anaesthesist 28: 207–220

    CAS  PubMed  Google Scholar 

  4. Alving BM, Hojima Y, Pisano JJ, Mason BL, Buckinham, RE, Mozen MM, Finlayson JS (1978) Hypotension associated with prekallikrein activator (Hagemann factor fragments) in plasma protein fraction. N Eng J Med 299: 66–70

    CAS  Google Scholar 

  5. Arturson G, Granath K, Thoren L, Wallenius G (1964) The renal excretion of low molecular weight dextran. Acta Chir Scand 127: 543–551

    Google Scholar 

  6. Bailey G, Strub RL, Klein RC, Salvaggio J (1967) Dextran — induced anaphylaxis. JAMA 200: 889–891

    CAS  PubMed  Google Scholar 

  7. Bauer A, Östling G (1970) Dextran — induced anaphylactoid reactions in connection with surgery. Acta Anaesthesiol. Scand (Suppl) 37: 182–185

    Google Scholar 

  8. Beez M, Dietl H (1979) Retrospektive Betrachtung der Häufigkeit anaphylaktoider Reaktionen nach Plasmasteril® und Longasteril®. Infusionstherapie 6: 23–26

    CAS  Google Scholar 

  9. Berg EM, Fasting S, Sellevold OFM (1991) Serious complications with dextran — 70 despite hapten prophylaxis. Is it best avoided prior to delivery? Anaesthesia 46: 1033–1035

    CAS  PubMed  Google Scholar 

  10. Bergentz SE, Falkheden T, Olsson S (1965) Diuresis and urinary viscosity in dehydrated patients: Influence of dextran 40000 with and without manitol. Ann Surg 161: 582–586

    CAS  PubMed Central  PubMed  Google Scholar 

  11. Bernstein RL, Rosenberg AD, Pada EY, Jaffe F (1987) A severe reaction to dextran despite hapten inhibition. Anesthesiology 67: 567–569

    CAS  PubMed  Google Scholar 

  12. Böttiger LE, Furhoff AK, Holmberg L (1979) Fatal reactions to drugs. Acta Med Scand 205: 451–456

    PubMed  Google Scholar 

  13. Bogan RK, Gale GR, Walton RP (1969) Fate of 14C-labelled hydroxyethyl starch m animals. Toxicol Appl Pharmacol 15: 206–211

    CAS  Google Scholar 

  14. Carr ME (1986) Effect of hydroxyethyl starch on the structure of thrombin- and reptilase-induced fibrin gels. J Lab Clin Med 108: 556–561

    CAS  PubMed  Google Scholar 

  15. Conrad St-A, Dietrich KA, Cullen AH, Levy GJ (1989) Cardiopulmonary response to red blood cell transfusion in critically ill non — surgical patients. Grit Care Med 17, 4, pt 2: 20

    Google Scholar 

  16. Czer LSC, and Shoemaker WC (1978) Optimal hematocrit value in critically ill postoperative patients. Surg Gynecol Obstet 147: 363–368

    CAS  PubMed  Google Scholar 

  17. Coombs RRA, Gell PGH (1975) Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell PGH et al. (eds) Clinical aspects of immunology, 3rd edn. Blackwell, Oxford, pp 761–781

    Google Scholar 

  18. Dhall RZ, Bryce NAJ, Dhall DP (1976) Effects of dextran on the molecular structure and tensile behaviour of human fibrin. Thromb Haemostas 35: 737–74

    CAS  Google Scholar 

  19. Dienes HP, Gerharz CD, Wagner R, Weber M, John HD (1986) Accumulation of hydroxyethyl starch (HES) in the liver of patients with renal failure and portal hypertension. J Hepatol 3: 223–227

    CAS  PubMed  Google Scholar 

  20. Dürr HK, Bode C, Krupinski R, Bode JC (1978) A comparison between naturally occuring macroamylasemia and macroamylasemia induced by hydroxyethyl starch. Eur J Clin Invest 8: 189–191

    PubMed  Google Scholar 

  21. Elliger J (1984) Experimentelle Untersuchung zur Elimination und Gewebespeicherung mittel- und niedermolekularer Hydroxyäthylstärke („HÄS-steril“ und „Expafusion“) Med Dissertation, Univ Frankfurt

    Google Scholar 

  22. Engberg A (1976) Effects of dextran 40 on the proximal renal tubule. Studies on transfer maxima of glucose and hippuran in the rat. Acta Chir Scand 142: 172–180

    CAS  PubMed  Google Scholar 

  23. Feest TG (1976) Low molecular weight dextran: a continuing cause of acute renal failure. Br Med J II: 1300

    Google Scholar 

  24. Flatau E, Resnitzky P (1980) Fatal anaphylactoid reactions after dextran 40 administration. JAMA 243: 1035–1036

    CAS  PubMed  Google Scholar 

  25. Forst H, Haller M, Adler M (1989) Effects of transfusion on systemic oxygen uptake: In: Vincent JL (ed) Update in intensive care and emergency medicine. Springer, Berlin Heidelberg New York Tokyo, pp 215–223

    Google Scholar 

  26. Furhoff AK (1977) Anaphylactoid reaction to dextran — a report of 133 cases. Acta Anesthesiol Scand 21: 161–167

    CAS  Google Scholar 

  27. Gilbert EM, Haupt MT, Mandanas RY, Huaringa AJ, Carlson RW (1986) The effect of fluid loading, blood transfusion, and catecholamine infusion on oxygen delivery and consumption in patients with sepsis. Am Rev Respirat Dis 134: 873–878

    CAS  Google Scholar 

  28. Gisselsson L, Rosberg B and Ericson M (1982) Myocardial blood flow, oxygen uptake and carbon-dioxide release of the human heart during haemodilution. Acta Anaesth Scand 26: 589–91

    CAS  PubMed  Google Scholar 

  29. Gofferje H, Hossil V (1977) Zur Hyperamylasämie nach Infusion von Hydroxyäthylstärke unterschiedlicher Molekulargewichtsverteilungen. Infusionstherapie 4: 141–144

    CAS  Google Scholar 

  30. Gruber UF, Saldeen T, Brokop T et al. (1980) Incidences of fatal postoperative pulmonary embolism after prophylaxis with dextran 70 and low-dose heparin: an international multicentre study. Br Med J 280: 69–72

    CAS  PubMed Central  PubMed  Google Scholar 

  31. Harke H, Pieper C, Meredig J, Rahman S, Rüssier P (1980) Rheologische und gerinnungsphysiologische Untersuchungen nach Infusion von HÄS 200/0,5 und Dextran 40. Anaesthesist 29: 71–77

    CAS  PubMed  Google Scholar 

  32. Hedin H (1977) Dextran-induced anaphylactoid reactions in man. Immunological in vitro and in vivo studies. Doc Thesis, Acta Univ Upsal

    Google Scholar 

  33. Hedin H, Richter W, Ring J (1976) Dextran-induced anaphylactoid reactions in man. Role of dextran-reactive antibodies. Int Arch Allergy Appl Immunol 52: 145–159

    CAS  PubMed  Google Scholar 

  34. Hehre EJ, Sugg JY, Neill JM (1952) The serological activity of dextrans. Ann NY Acad Sci 55: 467–470

    CAS  PubMed  Google Scholar 

  35. Hermann J, Gall H (1990) Diagnose und Therapie des persistierenden Pruritus nach Infusion von Hydroxyäthylstärke (HÄS). Akt Dermatol 16: 166–167

    Google Scholar 

  36. Hint H (1968) The pharmacology of dextran and the physiological background of the clinical use of rheomacrodex and macrodex. Acta Anaesth Belg 19: 119–38

    CAS  PubMed  Google Scholar 

  37. Hoelscher B (1975) Langzeitverträglichkeit hochdosierter Infusionen von Hydroxyäthylstärke und Dextran 60 bei normovolämischen Kaninchen. Infusionstherapie 2: 215–220

    Google Scholar 

  38. Hong B, Zhang T (1988) Studies on the side-effect of hydroxyethyl starch. J Pharmacol 108: 43

    Google Scholar 

  39. Hülse JD, Stoll RG, Yacobi A, Grupta SD, Lai CM (1980) Elimination of high molecular weight hydroxyethyl starch in rats. Res Commun Chem Pathol Pharmacol 29: 149–158

    PubMed  Google Scholar 

  40. Hülse JD, Yacobi A (1983) Hetastarch: An overview of the colloid and its metabo-lism.Durg Intell Clin Pharm 17: 334–341

    Google Scholar 

  41. Isbister JP, Fisher M McD (1980) Adverse effects of plasma volume expanders. Anaesth Intens Care 8: 145–151

    CAS  Google Scholar 

  42. Jesch F, Klövekorn WP, Sunder-Plassmann L, Seifert J, Meßmer K (1975) Hydroxyäthylstärke als Plasmaersatzmittel: Untersuchungen mit isovolämischer Hämodilution. Anaesthesist 24: 202–209

    CAS  PubMed  Google Scholar 

  43. Jesch F, Hübner G, Zumtobel V, Zimmermann M, Messmer K (1979) Hydroxyäthylstärke (HÄS 450/0,7) in Plasma und Leber. Konzentrationsverlauf und histologische Veränderungen beim Menschen. Infusionsther. Klin Ernähr 6: 112–117

    CAS  Google Scholar 

  44. Kabat EA, Bezer AE (1958) The effect of variation in molecular weight on the antigenicity of dextran in man. Arch Biochem Biophys 78: 306–318

    CAS  PubMed  Google Scholar 

  45. Kahn RC, Zaroulis C, Goetz W, Howland WS (1986) Hemodynamic oxygen transport and 2,3 — diphosphoglycerate changes after transfusion of patients in acute respiratory failure. Intens Care Med 12: 22–25

    CAS  Google Scholar 

  46. Köhler H, Kirch W, Horstmann HJ (1977) Die Bildung 2 hochmolekularer Komplexe aus Serumamylase und kolloidalen Plasmaersatzmitteln. Anaesthesist 26: 623–627

    PubMed  Google Scholar 

  47. Kowalyshyn Th-J, Prager D, Young J (1972) A review of the present status of preoperative hemoglobin requirements. Anesth Analg 51: 75–9

    CAS  PubMed  Google Scholar 

  48. Kraft D, Hedin H, Richter W, Scheiner O, Rumpold H, Devey ME (1982) Immunoglobulin class and subclass distribution of dextran reactive antibodies in human reactors and non reactors to clinical dextran. Allergy 37: 481–489

    CAS  PubMed  Google Scholar 

  49. Kraft D, Laubenthal H, Schimetta W, Scheiner O (1988) Immunologische Aspekte der Hydroxylethylstärke (HES) — Nebenwirkungen. Beitr Anaesth Intensivmed 26, 57–62

    Google Scholar 

  50. Kraft D, Sirtl C, Laubenthal et al. (1992) No evidence for the existence of preformed antibodies against hydroxyethyl-starch (HES) in man. Eur Surg Res 24: 138–142

    CAS  PubMed  Google Scholar 

  51. Landsteiner K (1921) Über heterogenetisches Antigen und Hapten. XV. Mitteilung über Antigene. Biopchemistry 119: 294–306

    CAS  Google Scholar 

  52. Laubenthal H (1986) Dextrananaphylaxie, Pathomechanismus und Prophylaxe. Ergebnisse einer multizentrischen klinischen Studie. Springer, Berlin Heidelberg New York Tokyo (Reihe Anaesthesiologie und Intensivmedizin, Bd 169)

    Google Scholar 

  53. Laubenthal H, Meßmer K (1981) Kommentar zu: W. Russ, U. Börner, V. Lüben: Schwerste anaphylaktoide Reaktion nach Infusion von 10%iger Hydroxyäthylstärke während der Narkose, Intensivmed Prax 4: 64–65

    Google Scholar 

  54. Laubenthal H, Peter K, Gruber UF, Gerber H, Meßmer K (1984) Multizentrische, klinische Studien mit monovalentem Haptendextran in der BRD und in der Schweiz. In: Mayrhofer O, Steinbereithner K, Bergmann H (Hrsg) Beiträge zur Anaesthesiologie und Intensivmedizin, Bd 3: Fortschritte der Dextran-Therapie. Maudrich, Wien München Bern, S 43–55

    Google Scholar 

  55. Laubenthal H, Richter W, Hedin H, Selbmann HK, Peter K, Meßmer K (1984) Stellungnahme zu „Herzstillstand unter Dextraninfusion trotz Haptenhemmung“ von B. Schöming, K. Sommer, H. Koch. Anästh Intensivther Notfallmed 19: 34–38 und 261–263

    Google Scholar 

  56. Laubenthal H, Sirtl C, Hügler P (1990) Inzidenz und Prävention dextranmduzierter Unverträglichkeitsreaktionen. In: Meßmer K Peter K (Hrsg) Infusionstherapie mit Dextranen. Neue Aspekte und Stellenwert. Zuckschwerdt, München Bern Wien, S 37–49

    Google Scholar 

  57. Lawrence DA, Schell RF (1985) Influence of hydroxyethyl starch on humoral and cell-mediated immune responses in mice. Transfusion 25: 223–229

    CAS  PubMed  Google Scholar 

  58. Lenz G, Hempel V, Junger H, Werle H, Buckmaier P (1986) Auswirkungen von Hydroxyäthylstärke, Oxypolygelatine und Humanalbumin auf die Phagozytosefunktion des RES gesunder Probanden. Anesthesist 35: 423–428

    CAS  Google Scholar 

  59. Lindblad G, Falk J (1976) Konzentrationsverlauf von Hydroxyäthylstärke und Dextran im Serum und Lebergewebe von Kaninchen und die histopathologischen Folgen der Speicherung von Hydroxyäthylstärke. Infusionsther Klin Ernähr 3: 301–303

    CAS  Google Scholar 

  60. Lungström KG, Renck H, Hedin H, Richter W, Rosberg B (1983) Prevention of dextran-induced anaphylactic reactions by hapten inhibition. I. A Scandinavian multi-center study on the effects of 10 ml dextran 1, 15 %, administered before dextran 70 or dextran 40. Acta Chir Scand 149: 341–348

    Google Scholar 

  61. Ljungström, KG, Renck H, Strandberg K, Hedin H, Richter W, Widerlöf E (1983) Adverse reactions to dextran in Sweden 1970–1979. Acta Chir Scand 149: 253–262

    PubMed  Google Scholar 

  62. Ljungström KG, Hedin H, Richter W, Wiholm BE (1988) Hapten inhibition and dextran anaphylaxis. Anaesthesia 43: 729–732

    PubMed  Google Scholar 

  63. Lorenz W, Doenicke A, Schöming B, Karges H, Schmal A (1981) Incidence and mechanisms of adverse reactions to polypeptides in man and dog. In: Hennessen W (ed) Dev. Biol. Standard., vol 48: Standardization of albumin, plasma substitutes and plasmapheresis. Karger, Basel München New York p 207–234

    Google Scholar 

  64. Lundsgaard-Hansen, P, Tschirren B (1980) Anaphylaktoide Reaktionen auf 102.787 Einheiten Gelatine. Allergologie 3: 76–78

    Google Scholar 

  65. Martin E, Hansen E, Peter K (1987) Acute limited normovolemic hemodilution: a method for avoiding homologous transfusion. World J Surg 11: 53–9

    CAS  PubMed  Google Scholar 

  66. Matheson NA (1966) Renal failure with low-molecular weight dextran Br Med J II: 1198

    Google Scholar 

  67. Matheson NA (1976) Les macromolecules et le rem. Anesth. Analg. Reanim 33: 615–619

    Google Scholar 

  68. Maunsbach AB, Madden SC, Latta H (1962) Light and electron microscopic changes in proximal tubules of rats after administration of glucose, mannitol sucrose or dextran. Lab Invest 11: 421–432

    CAS  PubMed  Google Scholar 

  69. Mendier C (1981) Haptenhemmung der dextran-induzierten anaphylaktischen Reaktionen beim Hund. Med Dissertation, Univ München

    Google Scholar 

  70. Messmer K (1975) Hemodilution. Surg Clin N Am 55: 659–78

    CAS  PubMed  Google Scholar 

  71. Messmer K (1981) Compensatory mechanisms for acute dilutional anemia. In: Schmid-Schönbein H, Messmer K, Rieger H (eds) Hemodilution and flow improvement. Bibl Haematol 47: 31–37

    PubMed  Google Scholar 

  72. Messmer K, Jesch F (1978) Volumenersatz und Hämodilution durch Hydroxyäthylstärke. Infusionstherapie 5: 169–177

    CAS  Google Scholar 

  73. Messmer K, Lorenz W, Sunder-Plassmann L, Kloevekorn W, Hutzel M (1970) Histamine release as cause of acute hypotension following rapid colloid infusion. Naunyn-Schmiedebergs Arch Pharmakol 267, 433–445

    CAS  PubMed  Google Scholar 

  74. Messmer K, Ljungström KG, Gruber UF, Richter W, Hedin H (1980) Prevention of dextran-induced anaphylactoid reactions by hapten inhibition. Lancet I: 975

    Google Scholar 

  75. Messmer K, Seemann C, Richter W, Hedin H, Laubenthal H (1981) Anaphylaktoide Reaktionen nach Dextran. L Tierexperimentelle Untersuchungen zum Prinzip der Haptenhemmung. In: Steinbereitner K, List WF (Hrsg) Beiträge zu Infusionstherapie und klinische Ernährung, Bd 8: Infusionstherapie mit Dextranen. Karger, Basel New York, S 66–81

    Google Scholar 

  76. Messmer K, Richter W, Takaori M (1984) Prinzip der Haptenhemmung zur Prophylaxe der Dextrananaphylaxie: Immunologische Aspekte. In: Mayrhofer O, Steinbereithner K, Bergmann H (Hrsg) Bd 3: Fortschritte der Dextrantherapie, Maudrich, Wien München Bern S 15–27

    Google Scholar 

  77. Messmer K, Kreimeier U, Intaglietta M (1986) Present state of intentional hemodilution. Eur Surg Res 18: 254–63

    CAS  PubMed  Google Scholar 

  78. Mirhashemi S, Ertefai S, Messmer K, Intaglietta M (1986) Diffusional oxygen loss from the arteriolar microvessels and the enhancement of tissue oxygenation by hemodilution due to increased microvascular flow velocity. Int J Microcirc Clin Exp 5: 277

    Google Scholar 

  79. Mirhashemi S, Ertefai S, Lindbom L, Lundberg K, Messmer K, Intaglietta M (1987) Microvascular effect of hemodilution Microvasc Res 6: 123

    CAS  Google Scholar 

  80. Mirhashemi S, Messmer K, Intaglietta M (1987) Tissue perfusion during normovolemic hemodilution investigated by a hydraulic model of the cardiovascular system. Int J Microcirc Clin Exp 6: 123–136

    CAS  PubMed  Google Scholar 

  81. Mishler JM, Dürr HK (1979) Macroamylasemia following the infusion of low molecular weight hydroxyethyl starch in man. Eur Surg Res 11: 217–222

    CAS  PubMed  Google Scholar 

  82. Mishler JM, Dürr HK (1980) Macroamylasemia induced by hydroxyethyl starch — confirmation by gel filtration analysis of serum and urine. Am J Clin Pathol 74: 387–391

    CAS  PubMed  Google Scholar 

  83. Morgan TO, Little JM (1967) Renal failure and low-molecular-weight dextran Br Med J I: 635

    Google Scholar 

  84. Parker NE, Porter JB, Williams HJM, Leftley N (1982) Pruritus after administration of hetastarch. Br Med J 284: 385–386

    CAS  Google Scholar 

  85. Parth E, Jurecka W, Schuller-Petrovic S, Gebhart W, Schimetta W, Scheiner O, Kraft D (1989) Itching after treatment with hydroxyethyl starch (HES). Skin Pathol 2: 235

    Google Scholar 

  86. Pauli J (1987) A prospective study of dextran-induced anaphylactoid reactions in 5.745 patients. Anaesth Intens Care 15: 163–167

    Google Scholar 

  87. Peter K, Laubenthal H, Gruber UF, Meßmer K (1984) Klinische Aspekte der Hemmung der Dextrananaphylaxie mit monovalentem Haptendextran. In: Mayrhofer O, Steinbereithner K, Bergmann H (Hrsg) Beiträge zur Anaesthesiologie und Intensivmedizin Bd 3: Fortschritte der Dextrantherapie. Maudrich, Wien München Bern, S 28–42

    Google Scholar 

  88. Rawstron RE (1976) Preoperative hemoglobin levels. Anesth Intens Care 4: 176–85

    CAS  Google Scholar 

  89. Renck H, Ljungström KG, Hedin H, Richter W (1983 a) Prevention of dextran-induced anaphylactic reactions by hapten inhibition. III. A Scandinavian multicenter study on the effect of 20 ml dextran 1, 15 %, administered before dextran 70 or dextran 40. Acta Chir Scand 149: 355–360

    CAS  PubMed  Google Scholar 

  90. Renck H, Ljungström KG, Rosberg B, Dhuner KG, Dahl S (1983 b) Prevention of dextran-induced anaphylactic reactions by hapten inhibition. II. A comparison of the effects of 20 ml dextran 1, 15 %, administered either admixed to or before dextran 70 or dextran 40. Acta Chir Scand 149: 349–353

    CAS  PubMed  Google Scholar 

  91. Revenäs B, Smedegard G, Hedin H, Richter W, Saldeen T (1980) Immune complex mediated anaphylactic shock in humans? In: Rügheimer E, Wawersik J, Zindler M (eds): 7th Wolrd.Congr Anaesthesiologists. Excerpta Medica, Amsterdam, pp 95–96

    Google Scholar 

  92. Revenäs B, Smedegard G, Saldeen T, Fredholm BB, Strandberg K (1981) Anaphylactic shock in monkeys passively sensitized with human reagenic serum. II Respiratory mechanics, hematology and metabolism. Acta Physiol Scand 111, 249–257

    PubMed  Google Scholar 

  93. Richter W (1971) Hapten inhibition of passive antidextran dextran anaphylaxis in guinea pigs. Role of molecular size in anaphylactogenicity and precipitability of dextran fractions. Int Arch Allerg 41: 826–844

    CAS  PubMed  Google Scholar 

  94. Richter AW, Hedin HJ (1982) Dextran hypersensitivity. Immunol. Today 3: 132–138

    Google Scholar 

  95. Richter W, Hedin H, Ring J (1977) Immunologische Befunde bei der Infusion kolloidaler Lösungen Med Welt 28: 1717–1719

    CAS  Google Scholar 

  96. Richter W, Seemann C, Hedin H, Ring J, Meßmer K (1980) Dextranunverträglichkeit. Immunologische tierexperimentelle und klinische Studien. Med Welt 31: 365–369

    CAS  PubMed  Google Scholar 

  97. Ring J (1978) Anaphylaktoide Reaktionen nach Infusionen natürlicher und künstlicher Kolloide. Springer, Berlin Heidelberg New York Tokyo (Reihe Anaesthesiologie und Intensivmedizin, Bd 111)

    Google Scholar 

  98. Ring J (1985) Anaphylactoid reactions to plasma substitutes. Int Anesth Clin 23, 67

    CAS  Google Scholar 

  99. Ring J, Messmer K (1976) Anaphylaktoide Reaktionen nach Infusion kolloidaler Volumenersatzmittel. Internist Prax 16: 579–588

    Google Scholar 

  100. Ring J, Messmer K (1977) Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet I: 466–469

    Google Scholar 

  101. Ring J, Richter W (1980) Wirkungsmechanismus unerwünschter Reaktionen von Hydroxyläthylstärke (HÄS) und Humanalbumin. Allergologie 3: 79–86

    CAS  Google Scholar 

  102. Russ W, Börner U, Lüben V (1981) Schwerste anaphylaktoide Reaktion nach Infusion von 10%iger Hydroxyäthylstärke während der Narkose. Intensivmed Prax 4: 62–64

    Google Scholar 

  103. Schneider W, Köster HJ (1966) Zur Beurteilung von Transfusionsreaktionen. Konsequenzen für die Praxis MMW 108: 1478

    Google Scholar 

  104. Schöning B, Koch H (1975) Pathergiequote verschiedener Plasmasubstitute an Haut und Respirationstrakt orthopädischer Patienten. Anaesthesist 24: 507–516

    PubMed  Google Scholar 

  105. Schöning B, Koch H (1984) Herzstillstand unter Dextraninfusion trotz Haptenhemmung. Anaesth Intensivther Notfallmed 19:34–38

    Google Scholar 

  106. Schöning B, Lorenz W (1981) Prevention of allergoid (cutaneous anaphylactoid) reactions to polygeline (Haemaccel®) in orthopaedic patients by premedication with H1and H2 receptor antagonist. In: Hennessen W (ed) Dev. Biol. Standard., vol 48: Standardization of albumin, plasma substitutes and plasmapheresis Karger. Basel New York, p 241–249

    Google Scholar 

  107. Sellner W, Jurecka W (1991) Therapieresistenter Pruritus nach Verabreichung von Hydroxyäthylstärke. Jahrestagung Österr. Ges. Dermatol Venerol Graz (21.–23.06.)

    Google Scholar 

  108. Seiler FR, Quast O, Sedlacek HH, Schneider H, Hammer R (1980) Humanalbumin als Plasma-Ersatzmittel. Allergologie 3: 87

    Google Scholar 

  109. Shibutani K, Komatsu T, Kubal K, Sanchala V, Kumar V, Bizzari DV (1983) Critical level of oxygen delivery in anaesthetized man. Crit Care Med 11: 640–643

    CAS  PubMed  Google Scholar 

  110. Shatney CH, Chaudry IH (1984) Hydroxyethyl starch administration does not depress reticuloendothelial function or increase mortaility from sepsis. Circ Shock 13: 21–26

    CAS  PubMed  Google Scholar 

  111. Shoemaker WC (1984) Pathophysiology and therapy of shock syndromes. In: Shoemaker WC, Thompson WL, Holbrook PR (eds) Textbook of critical care. Saunders, Philadelphia, pp 52–72

    Google Scholar 

  112. Sirtl C, Hübner G, Jesch F (1988) Zur Speicherung von Hydroxyäthylstärke (HÄS) im menschlichen Gewebe.Peter K, Schimetta W, Bergmann H, Gerlach E, Messmer K, Steinbereithner K (Hrsg) Beiträge zur Anaesthesiologie und Intensivmedizin, Bd 26: Hydroxyäthylstärke (HES). Aktuelle Theorie und Praxis. Maudrich, Wien München Bern, S 74–97

    Google Scholar 

  113. Smedegard G (1980) Anaphylactic shock. Pathophysiology of aggregate and cytotropic anaphylaxis in the monkey. Doctoral thesis. Acta Univers Upsal.

    Google Scholar 

  114. Strauss RG (1981) Review of the effects of hydroxyethyl starch on the blood coagulation system. Transfusion 21: 299–302

    CAS  PubMed  Google Scholar 

  115. Strauss RG, Stump DC, Henriksen RA, Saunders R (1985) Effects of hydroxyethyl starch on fibrinogen, fibrin clot formation, and fibrinolysis. Transfusion 25: 230–234

    CAS  PubMed  Google Scholar 

  116. Strauss R, Snyder EL, Stuber J, Fick RB (1986) Ingestion of hydroxyethylstarch by human leucocytes. Transfusion 26: 88

    CAS  PubMed  Google Scholar 

  117. Strauss RG, Stansfield G, Henriksen A, Villhauer PJ (1988) Pentastarch may cause fewer effects on coagulation than hetastarch. Transfusion 28: 257–260

    CAS  PubMed  Google Scholar 

  118. Stump DC, Strauss RG, Henriksen RA, Petersen RE, Saunders R (1985) Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII. Transfusion 25: 349–354

    CAS  PubMed  Google Scholar 

  119. Sunder-Plasssmann L, Klövekorn WP, Hase U, Messmer K (1971) The physiological significance of acutely induced hemodilution. In: Ditzel R, Lewis D (eds) Congr Microcirculation. Karger, Basel, pp 23–28

    Google Scholar 

  120. Sunder-Plassmann L, Klövekorn WP, Messmer K (1976) Präoperative Hämodilution: Grundlagen, Adaptationsmechanismen und Grenzen klinischer Anwendung. Anaesthesist 25: 124–30

    CAS  PubMed  Google Scholar 

  121. Thompson WL (1976) Toxicities to dextrans. Transfusion 16: 90

    CAS  PubMed  Google Scholar 

  122. Thompson WL, Fukushima T, Rutherford RB, Walton RP (1970) Intravascular persistence, tissue storage and excretion of hydroxyethylstarch. Surg Gynecol Obstet 31: 965–972

    Google Scholar 

  123. Thoren L (1978) Dextran as a plasma volume substitute. Prog Clin Biol Res 19: 265–282

    CAS  PubMed  Google Scholar 

  124. Vandamme JP (1975) Severe and fatal reactions to rheomacrodex. Acta Chir Belg 5: 531–545

    Google Scholar 

  125. Vickery AL (1956) The fate of dextran in tissues of the acutely wounded; a study of the histologic localization of dextran in tissues of Korean battle casualties. Am J Pathol 32: 161–183

    CAS  PubMed Central  PubMed  Google Scholar 

  126. Waldhausen E, Brinke G, Nagel A, Lohmann R (1975) Allergische Reaktionen nach Dextraninfusionen. Anaesthesist 24: 129–135

    CAS  PubMed  Google Scholar 

  127. Waldhausen E, Marquardt B, Helms U (1981) Erfahrungen aus 31 anaphylaktoiden Reaktionen. Anaesthesist 30: 47–51

    CAS  PubMed  Google Scholar 

  128. Weis KH (1983) Haemaccel 35: Nebenreaktionen in einer multizentrischen, prospektiven Studie. Anaesthesist 32: 488–493

    CAS  PubMed  Google Scholar 

  129. Wells JV, King MA (1980) Adverse reactions to human plasma proteins. Anaesth Intens Care 8, 139

    CAS  Google Scholar 

  130. Wells JV, Buckley RH, Schonfield MS, Fudenberg HH (1977) Anaphylactic reactions to plasma infusions in patients with hypogammaglobulinemia and anti-IgA antibodies. Clin Immunol Immunopathol 8: 265–271

    CAS  PubMed  Google Scholar 

  131. White KL, Krasula RW, Munson AE, Holsapple MP (1986) Effects of hydroxyethyl starch (Hespan), a plasma expander, on the functional activity of the reticulo-endothelial system. Comparison with human serumalbumin and pyran copolymer. Drug Chem Toxicol 9: 305–322

    CAS  PubMed  Google Scholar 

  132. Wilkinson AW (1956) Dextran without reactions. Lancet II: 604–606

    Google Scholar 

  133. Wilkinson AW, Storey JD (1953) Reactions to dextran. Lancet II: 956–958

    Google Scholar 

  134. Ziegler HK (1978) Sektionsbefund bei Dextranzwischenfall. Med Klin 73: 1089–1090

    CAS  PubMed  Google Scholar 

Download references

Authors
  1. H. Laubenthal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Sirtl
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Anaesthesiologie, Universität Erlangen-Nürnberg, Krankenhausstr. 12, D-W-8520, Erlangen, Germany

    E. Rügheimer Prof. Dr. med.

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Laubenthal, H., Sirtl, C. (1993). Risiko kolloidaler Lösungen und Grenzen der Hämodilution. In: Rügheimer, E. (eds) Konzepte zur Sicherheit in der Anästhesie. Klinische Anästhesiologie und Intensivtherapie, vol 42. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77781-3_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-77781-3_19

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-55931-3

  • Online ISBN: 978-3-642-77781-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation